Cas:41008-78-0 Poly(N-ethyl-2-vinylcarbazole) manufacturer & supplier

Chemical Name:Poly(N-ethyl-2-vinylcarbazole)

CAS.NO:41008-78-0

Synonyms:9H-Carbazole, 2-ethenyl-9-ethyl-;9-Ethyl-2-vinyl-9H-carbazole;MFCD06798821

Molecular Formula:C₁₆H₁₅N

Molecular Weight:221.297

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:388.1±25.0 °C at 760 mmHg

Density:1.0±0.1 g/cm3

Index of Refraction:1.591

PSA:

Exact Mass:221.120453

LogP:5.00

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 9H-Carbazole, 2-ethenyl-9-ethyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD06798821 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9-Ethyl-2-vinyl-9H-carbazole Use and application,MFCD06798821 technical grade,usp/ep/jp grade.

Related News: As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. Poly(N-ethyl-2-vinylcarbazole) manufacturer International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation. Poly(N-ethyl-2-vinylcarbazole) supplier As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. Poly(N-ethyl-2-vinylcarbazole) vendor You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs. Poly(N-ethyl-2-vinylcarbazole) factory The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.